Article

Routine NSAID use questioned based on multiple factors

Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are often used off-label for multiple purposes in cataract surgery, but such treatment is often being administered with limited supporting evidence and carries a high cost along with potential risks, said Walter Stark, MD, at Spotlight on Cataracts 2007.

Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are often used off-label for multiple purposesin cataract surgery, but such treatment is often being administered with limited supporting evidenceand carries a high cost along with potential risks, said Walter Stark, MD, at Spotlight on Cataracts2007.

The only approved indications for topical NSAIDs in cataract surgery are to treat postoperative painor inflammation. However, these agents are being prescribed off-label outside of those intended usesto potentiate mydriasis as well as to prevent or treat cystoid macular edema (CME).

A few studies have shown topical NSAIDs increase pupil size and decrease constriction. However, gooddata are lacking to show a benefit for CME prevention. When used in eyes with persistent CME, topicalNSAID use has been shown to provide a good response measured by improvement in lines of vision.However, CME recurred within a few months after the medication was stopped in one study.

"At an average wholesale cost of about $79 dollars per bottle and up to $130 retail multiplied by 2.5million cataract operations performed annually, topical NSAID use can add $250 million to the cost ofcare. In addition to the economic consequences, surgeons need also consider use of these agents mightcause complications, including corneal melt," Dr. Stark said.

Dr. Stark told attendees he uses topical NSAIDs preoperatively, administering four doses beginning 1hour prior to surgery when starting the dilating drops. However, in eyes predisposed to CME,prophylactic treatment is initiated 1 to 3 days preoperatively and continued for 2 to 3 weeks aftersurgery.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.